IL6 and COVID-19: Contrary to this chronic disease, COVID-19 may be assimilated to an acute infection and thus, may not require an anti-IL6 effect as prolonged as in rheumatoid arthritis, which may explain how clinical efficacy was obtained so quickly in the present study.